Central Lab Market Research Report
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Central Lab Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Central Lab Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.2. Strategies Adopted by Top 3 Players
5.3. Impact of Cell and Gene Therapy on Central Lab Market
5.4. Impact of Clinical Trial on Central Lab Market
5.5. Central Lab Market: SWOT Analysis
6. Global Central Lab Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Genetic Services
6.3.2. Biomarker Services
6.3.3. Microbiology Services
6.3.4. Anatomic Pathology/Histology
6.3.5. Specimen Management & Storage
6.3.6. Special Chemistry Services
6.3.7. Clinical Research & Trial Services
6.3.8. Others
6.4. Market Attractiveness Analysis, by Product
7. Global Central Lab Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Pharmaceutical Companies
7.3.2. Biotechnology Companies
7.3.3. Academic and Research Institutes
7.4. Market Attractiveness Analysis, by End-user
8. Global Central Lab Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East and Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Central Lab Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product, 2017–2031
9.2.1. Genetic Services
9.2.2. Biomarker Services
9.2.3. Microbiology Services
9.2.4. Anatomic Pathology/Histology
9.2.5. Specimen Management & Storage
9.2.6. Special Chemistry Services
9.2.7. Clinical Research & Trial Services
9.2.8. Others
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Pharmaceutical Companies
9.3.2. Biotechnology Companies
9.3.3. Academic and Research Institutes
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By End-user
9.5.3. By Country
10. Europe Central Lab Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017–2031
10.2.1. Genetic Services
10.2.2. Biomarker Services
10.2.3. Microbiology Services
10.2.4. Anatomic Pathology/Histology
10.2.5. Specimen Management & Storage
10.2.6. Special Chemistry Services
10.2.7. Clinical Research & Trial Services
10.2.8. Others
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Pharmaceutical Companies
10.3.2. Biotechnology Companies
10.3.3. Academic and Research Institutes
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Central Lab Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Genetic Services
11.2.2. Biomarker Services
11.2.3. Microbiology Services
11.2.4. Anatomic Pathology/Histology
11.2.5. Specimen Management & Storage
11.2.6. Special Chemistry Services
11.2.7. Clinical Research & Trial Services
11.2.8. Others
11.3. Market Value Forecast, by End-user, 2017–2031
11.3.1. Pharmaceutical Companies
11.3.2. Biotechnology Companies
11.3.3. Academic and Research Institutes
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Central Lab Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Genetic Services
12.2.2. Biomarker Services
12.2.3. Microbiology Services
12.2.4. Anatomic Pathology/Histology
12.2.5. Specimen Management & Storage
12.2.6. Special Chemistry Services
12.2.7. Clinical Research & Trial Services
12.2.8. Others
12.3. Market Value Forecast, by End-user, 2017–2031
12.3.1. Pharmaceutical Companies
12.3.2. Biotechnology Companies
12.3.3. Academic and Research Institutes
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East and Africa Central Lab Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Genetic Services
13.2.2. Biomarker Services
13.2.3. Microbiology Services
13.2.4. Anatomic Pathology/Histology
13.2.5. Specimen Management & Storage
13.2.6. Special Chemistry Services
13.2.7. Clinical Research & Trial Services
13.2.8. Others
13.3. Market Value Forecast, by End-user, 2017–2031
13.3.1. Pharmaceutical Companies
13.3.2. Biotechnology Companies
13.3.3. Academic and Research Institutes
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East and Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. ACM Global Central Lab
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Barc Lab (Cerba Research)
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Bioscientia (Sonic Healthcare)
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Celerion
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. CIRION BioPharma Research
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Clinical Reference Laboratory
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Eurofins Central Laboratory
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Frontage Laboratories, Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. ICON Central Labs.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. INTERLAB Central Lab Services.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Company Financials
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis
14.3.11. InVitro International
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Company Financials
14.3.11.3. Growth Strategies
14.3.11.4. SWOT Analysis
14.3.12. Lab Corp/Covance
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Company Financials
14.3.12.3. Growth Strategies
14.3.12.4. SWOT Analysis
14.3.13. LabConnect
14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.13.2. Company Financials
14.3.13.3. Growth Strategies
14.3.13.4. SWOT Analysis
14.3.14. Medpace
14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.14.2. Company Financials
14.3.14.3. Growth Strategies
14.3.14.4. SWOT Analysis
14.3.15. MLM Medical Labs GmbH.
14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.15.2. Company Financials
14.3.15.3. Growth Strategies
14.3.15.4. SWOT Analysis
14.3.16. PPD
14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.16.2. Company Financials
14.3.16.3. Growth Strategies
14.3.16.4. SWOT Analysis
14.3.17. Q² Solutions
14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.17.2. Company Financials
14.3.17.3. Growth Strategies
14.3.17.4. SWOT Analysis
14.3.18. Synevo Central Lab
14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.18.2. Company Financials
14.3.18.3. Growth Strategies
14.3.18.4. SWOT Analysis
14.3.19. Other Prominent Players
14.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.19.2. Company Financials
14.3.19.3. Growth Strategies
14.3.19.4. SWOT Analysis